Drug Trial Radar · NCT07136805
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
154
Actual
Start
Nov 25, 2025
Primary completion
Dec 31, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- VivaVision Biotech, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
Conditions
- Non-infectious Anterior Uveitis
Interventions
VVN461 Ophthalmic Solution 1.0%Drug
1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
1.0% prednisolone acetateDrug
1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in anterior chamber cell (ACC) grade in the study eye at Day 14Time frame: Day 14
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.